Both studies suggest that the IL-1R inhibitor Anakinra corrects transcriptional changes, restores MeCP2 levels and spine plasticity, and ameliorates cognitive defects: these conclusions are consistent with the trend we observed in cells with MECP2 duplication, where it is plausible to infer that the extra copies of both MECP2 and IRAK1 amplify the response to IL-1beta and exert a synergistic disruptive effect on MECP2 levels, exacerbating the consequent deleterious effects on synapses. The gene discussed is IRAK1; the disease is Cognitive impairment.